606,700 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Bought by Two Sigma Advisers LP

Two Sigma Advisers LP acquired a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 606,700 shares of the company's stock, valued at approximately $1,432,000. Two Sigma Advisers LP owned about 1.26% of Cassava Sciences as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SAVA. Two Sigma Investments LP increased its stake in shares of Cassava Sciences by 679.1% in the fourth quarter. Two Sigma Investments LP now owns 562,082 shares of the company's stock worth $1,327,000 after buying an additional 489,936 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Cassava Sciences in the 4th quarter valued at approximately $117,000. Ensign Peak Advisors Inc raised its holdings in shares of Cassava Sciences by 122.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 36,496 shares of the company's stock worth $86,000 after purchasing an additional 20,100 shares during the period. Deutsche Bank AG raised its stake in Cassava Sciences by 42.7% during the fourth quarter. Deutsche Bank AG now owns 36,571 shares of the company's stock worth $86,000 after acquiring an additional 10,940 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Cassava Sciences by 638.0% during the fourth quarter. BNP Paribas Financial Markets now owns 64,561 shares of the company's stock valued at $152,000 after acquiring an additional 55,813 shares during the period. 38.05% of the stock is currently owned by hedge funds and other institutional investors.

Cassava Sciences Stock Performance

Shares of NASDAQ:SAVA traded up $0.01 during trading hours on Wednesday, hitting $2.17. 216,630 shares of the company's stock traded hands, compared to its average volume of 3,005,949. The company has a market cap of $104.59 million, a price-to-earnings ratio of -1.57 and a beta of -2.00. Cassava Sciences, Inc. has a 52 week low of $1.15 and a 52 week high of $42.20. The company's fifty day simple moving average is $1.66 and its two-hundred day simple moving average is $3.21.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.48) earnings per share (EPS) for the quarter. On average, analysts anticipate that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 target price on shares of Cassava Sciences in a research report on Tuesday, March 25th.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.